Response to desmopressin as a function of urine osmolality in the treatment of monosymptomatic nocturnal enuresis: a double-blind prospective study

What Was Tested

This randomized controlled trial paper looks at Vasopressin and Desmopressin.

To determine if urine osmolality parameters can predict whether children with primary monosymptomatic nocturnal enuresis will respond to desmopressin, the researchers conducted a prospective, double-blind, placebo-controlled study in 96 children 8 to 14 years old.

Why It Was Studied

Urine specimens for osmolality were collected at 6 p.m. and 6 a.m. on 3 consecutive days during the baseline and the 2, 14-day treatment periods.

Who Took Part

According to the abstract, 96 children were involved.

PubMed indexes the participants as children and teenagers, both men and women.

Following a 2-week baseline screening interval patients with at least 6 of 14 net nights were randomized to double-blind regimens of desmopressin or placebo.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

Random assignment meant chance, not the researchers, decided who got Vasopressin and who got the comparison, which limits bias.

Neither the children nor the staff measuring them knew who was on Vasopressin, so expectations could not easily colour the readings.

The comparison arm used a placebo, so changes seen with Vasopressin could be set against what happens without it.

What Was Measured

The subject headings attached to it are Deamino Arginine Vasopressin, Enuresis, Osmolar Concentration and Urine.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vasopressin and Desmopressin in 96 children.

The publication is from 1995 (The Journal of urology), a journal based in United States.

More context: the Vasopressin compound page and the Desmopressin compound page, all human trials.